Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlin L Robb

Showing results (341-350 of 358) with videos related to

Pageof 36
Sort By:
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens|August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
Plos Pathogens|September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature|September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
The New England Journal of Medicine|September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineAnn R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
The Lancet. HIV|March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meetingBoris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Pageof 36

Showing results (341-350 of 358) with videos related to

Sort By:
Pageof 36
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens|August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
Plos Pathogens|September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature|September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
The New England Journal of Medicine|September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineAnn R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
The Lancet. HIV|March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meetingBoris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Pageof 36